This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The AstraZeneca PLC ADR AZN slid 1.24% to $71.93 Monday, on what proved to be an all-around favorable trading session for the ...

AstraZeneca PLC closed 21.02% short of its 52-week high of £133.88, which the company reached on September 3rd.

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in ...

AstraZeneca PLC has agreed to pay $51 million to settle claims it entered into an unlawful deal to limit competition for ...

May 31 (Reuters) - An experimental treatment by Pfizer (PFE.N), opens new tab and Arvinas (ARVN.O), opens new tab delayed progression of breast cancer by more than three months compared to ...

By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at ...

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP). The drugmaker said ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer. Tremelimumab ...